Zydus Lifesciences Ltd
In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 14,253 crores in FY20.
Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe
- Market Cap ₹ 98,792 Cr.
- Current Price ₹ 982
- High / Low ₹ 1,324 / 795
- Stock P/E 21.2
- Book Value ₹ 238
- Dividend Yield 1.12 %
- ROCE 24.4 %
- ROE 21.3 %
- Face Value ₹ 1.00
Pros
- Company has been maintaining a healthy dividend payout of 21.1%
- Debtor days have improved from 84.7 to 63.2 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE 500 BSE Healthcare BSE 200 Nifty Next 50 Nifty 500
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
7,224 | 8,651 | 9,427 | 9,376 | 11,905 | 13,166 | 14,253 | 14,404 | 15,110 | 17,237 | 19,547 | 23,242 | |
6,021 | 6,896 | 7,095 | 7,474 | 9,074 | 10,174 | 11,455 | 11,013 | 11,768 | 13,378 | 14,163 | 16,183 | |
Operating Profit | 1,203 | 1,756 | 2,332 | 1,902 | 2,831 | 2,991 | 2,798 | 3,391 | 3,342 | 3,860 | 5,384 | 7,058 |
OPM % | 17% | 20% | 25% | 20% | 24% | 23% | 20% | 24% | 22% | 22% | 28% | 30% |
30 | 45 | 112 | 127 | 111 | 183 | -264 | -231 | 2,581 | -422 | 293 | 50 | |
Interest | 90 | 68 | 53 | 45 | 91 | 194 | 342 | 159 | 127 | 130 | 81 | 166 |
Depreciation | 201 | 287 | 292 | 373 | 539 | 599 | 696 | 670 | 713 | 723 | 764 | 916 |
Profit before tax | 942 | 1,446 | 2,099 | 1,612 | 2,312 | 2,382 | 1,495 | 2,331 | 5,084 | 2,585 | 4,832 | 6,027 |
Tax % | 11% | 18% | 8% | 8% | 24% | 22% | 21% | 8% | 10% | 23% | 20% | 23% |
836 | 1,188 | 1,964 | 1,517 | 1,810 | 1,899 | 1,204 | 2,185 | 4,618 | 2,092 | 3,973 | 4,673 | |
EPS in Rs | 7.85 | 11.24 | 18.89 | 14.53 | 17.35 | 18.06 | 11.49 | 20.84 | 43.83 | 19.37 | 38.36 | 44.97 |
Dividend Payout % | 23% | 21% | 17% | 22% | 20% | 19% | 30% | 17% | 6% | 31% | 8% | 24% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 10% |
3 Years: | 15% |
TTM: | 19% |
Compounded Profit Growth | |
---|---|
10 Years: | 15% |
5 Years: | 26% |
3 Years: | 2% |
TTM: | 21% |
Stock Price CAGR | |
---|---|
10 Years: | 11% |
5 Years: | 21% |
3 Years: | 40% |
1 Year: | -10% |
Return on Equity | |
---|---|
10 Years: | 21% |
5 Years: | 21% |
3 Years: | 19% |
Last Year: | 21% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 102 | 101 | 101 | 101 |
Reserves | 3,337 | 4,149 | 5,597 | 6,858 | 8,642 | 10,284 | 10,273 | 12,890 | 16,897 | 17,415 | 19,729 | 23,852 |
2,700 | 2,651 | 2,442 | 5,207 | 5,407 | 7,899 | 7,986 | 4,608 | 4,221 | 1,195 | 804 | 3,213 | |
1,847 | 2,144 | 2,208 | 2,937 | 3,632 | 4,945 | 5,115 | 6,165 | 6,421 | 6,851 | 8,201 | 10,035 | |
Total Liabilities | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 37,202 |
3,124 | 3,352 | 3,748 | 5,755 | 6,483 | 12,164 | 12,230 | 12,133 | 12,188 | 11,521 | 12,368 | 14,508 | |
CWIP | 892 | 798 | 951 | 1,543 | 1,527 | 837 | 742 | 783 | 726 | 1,201 | 2,423 | 1,318 |
Investments | 87 | 154 | 416 | 435 | 746 | 674 | 765 | 830 | 3,288 | 1,547 | 1,220 | 6,408 |
3,885 | 4,743 | 5,235 | 7,371 | 9,028 | 9,556 | 9,740 | 10,019 | 11,439 | 11,294 | 12,822 | 14,968 | |
Total Assets | 7,986 | 9,047 | 10,350 | 15,104 | 17,783 | 23,231 | 23,477 | 23,765 | 27,642 | 25,562 | 28,834 | 37,202 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
903 | 994 | 1,894 | 1,312 | 919 | 1,282 | 2,932 | 3,294 | 2,104 | 2,689 | 3,228 | 6,777 | |
-438 | -465 | -860 | -2,872 | -974 | -3,977 | -1,004 | -837 | -1,018 | 1,542 | -1,492 | -8,372 | |
-529 | -351 | -935 | 2,316 | 52 | 1,885 | -1,528 | -2,548 | -868 | -4,400 | -1,810 | 2,014 | |
Net Cash Flow | -64 | 178 | 99 | 756 | -3 | -811 | 399 | -90 | 219 | -170 | -75 | 419 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 57 | 67 | 68 | 89 | 98 | 110 | 94 | 79 | 81 | 94 | 97 | 63 |
Inventory Days | 184 | 175 | 158 | 193 | 211 | 208 | 207 | 246 | 245 | 197 | 202 | 227 |
Days Payable | 123 | 125 | 154 | 165 | 167 | 149 | 152 | 168 | 141 | 123 | 125 | 133 |
Cash Conversion Cycle | 119 | 118 | 71 | 116 | 142 | 169 | 149 | 158 | 185 | 168 | 175 | 158 |
Working Capital Days | 46 | 56 | 46 | 62 | 95 | 99 | 79 | 95 | 112 | 95 | 103 | 129 |
ROCE % | 17% | 23% | 28% | 16% | 18% | 15% | 11% | 14% | 13% | 15% | 22% | 24% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
14h - Zydus receives USFDA EIR for Dabhasa API facility; inspection classified as VAI and closed.
-
ESG Rating
7 Jun - Received independent ESG rating of 67 from NSE Sustainability Ratings on June 6, 2025.
-
Announcement under Regulation 30 (LODR)-Acquisition
3 Jun - Zydus acquires 5.9% stake in Agenus for USD 16M to expand immuno-oncology pipeline.
-
Definitive Exclusive Licensing Agreement With Agenus Inc., USA
3 Jun - Zydus licenses Botensilimab and Balstilimab from Agenus for India/Sri Lanka, advancing cancer therapy portfolio.
-
Announcement under Regulation 30 (LODR)-Acquisition
3 Jun - Zydus to acquire US biologics facilities from Agenus for $75M upfront plus $50M contingent payments.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2012
from nse
-
Financial Year 2011
from bse
Concalls
-
May 2025Transcript PPT
-
Mar 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT REC
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT REC
-
Aug 2024TranscriptNotesPPT REC
-
May 2024Transcript PPT
-
Feb 2024Transcript PPT
-
Nov 2023Transcript PPT
-
Sep 2023Transcript PPT
-
Aug 2023Transcript PPT
-
May 2023Transcript PPT
-
Feb 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022Transcript PPT
-
Feb 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021TranscriptPPT
-
Aug 2021Transcript PPT
-
May 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptPPT
-
Aug 2020TranscriptNotesPPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptPPT
-
Mar 2020TranscriptPPT
-
Feb 2020TranscriptNotesPPT
-
Feb 2020TranscriptNotesPPT
-
Nov 2019TranscriptPPT
-
Jul 2019TranscriptPPT
-
Jun 2019Transcript PPT
-
Jan 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Jun 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Nov 2017TranscriptNotesPPT
-
Sep 2017TranscriptNotesPPT
-
Jun 2017Transcript PPT
-
Mar 2017TranscriptNotesPPT
-
Feb 2017TranscriptNotesPPT
-
Jan 2017TranscriptPPT
-
Nov 2016Transcript PPT
-
May 2016Transcript PPT
Business Segments